APR 20, 2016 9:22 AM PDT

New 'Game Changer' Drug for Head and Neck Cancer

WRITTEN BY: Xuan Pham

Immunotherapy, the technique of using the immune system to fight off disease, is one of the most promising avenues for anticancer treatments. And this route seems to be paying off, as researchers announced a new immune drug that’s more effective than traditional chemotherapy against aggressive head and neck cancers.

Image credit: Pixabay.com

The drug is called nivolumab, and belongs to a class of medicines called PD-1 immune checkpoint inhibitors. Essentially this drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. The drug is marketed under the name Opdivo by Bristol-Myers Squibb, and is FDA-approved for the treatment of other cancer types, including melanoma, lung and kidney cancer.
 
"We don't have effective treatments for advanced head and neck cancers - these cancers are notoriously difficult to treat. So it's exciting that this phase III trial has been the first to show a significant survival benefit with an immunotherapy," said Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and the senior study author. "Once it has relapsed or spread, head and neck cancer is extremely difficult to treat, with surgery and radiotherapy often impossible. So it's very good news for patients that these interim results indicate we now have a new treatment that works, and can significantly extend life."
 
In a phase III clinical trial, researchers compared nivolumab in 240 head and neck cancer patients versus 121 patients who were given the traditional chemotherapy. The team found, within one year, patient survival rate for nivolumab (36 percent) was more than doubled that of standard chemotherapy (17 percent). The results from this trial, called Checkmate-141, were reported in the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
 
"Nivolumab was not only more effective than chemotherapy for patients with head and neck cancer but also had fewer side-effects, and has the potential to significantly extend life and increase quality of life,” Harrington added. They reported side effects were seen in about 13 percent of patients on nivolumab, whereas over 35 percent of patients on standard chemotherapy had side effects.
 
Because its effectiveness was so apparent, the clinical trial ended early and patients on standard chemo treatments were given the option to switch to nivolumab.
 
“We are encouraged by the overall survival results seen with this investigational use of nivolumab versus three standards of care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who often face poor survival rates. These findings are supportive of our Immuno-Oncology research goal to study potential treatment options for their ability to help patients with difficult-to-treat cancers achieve long-term survival,” said Jean Viallet, Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.
 


Additional sources: MNT, BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
SEP 30, 2020
Cancer
How to avoid endocrine disrupting chemicals in your life
SEP 30, 2020
How to avoid endocrine disrupting chemicals in your life
While few people actually enjoy reading product labels and ingredients, a new study from Silent Spring Institute suggest ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
OCT 15, 2020
Cancer
How is mole growth really associated to skin cancer?
OCT 15, 2020
How is mole growth really associated to skin cancer?
New research published in the journal eLife questions the way we think about skin cancer. Focused on mole growth, the st ...
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
Loading Comments...